# Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

> **NCT05425940** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Exelixis** · enrollment: 901 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** XL092
- **DRUG:** Atezolizumab
- **DRUG:** Regorafenib

## Key facts

- **NCT ID:** NCT05425940
- **Lead sponsor:** Exelixis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-09-07
- **Primary completion:** 2026-05
- **Final completion:** 2027-01
- **Target enrollment:** 901 (ACTUAL)
- **Last updated:** 2025-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05425940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05425940, "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05425940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*